These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 31164373)

  • 21. Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials.
    D'Angelo SP; Mahoney MR; Van Tine BA; Atkins J; Milhem MM; Jahagirdar BN; Antonescu CR; Horvath E; Tap WD; Schwartz GK; Streicher H
    Lancet Oncol; 2018 Mar; 19(3):416-426. PubMed ID: 29370992
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Thoracic stop-flow perfusion in the treatment of refractory malignant pleural mesothelioma: a phase I-II evaluation/trial.
    Guadagni S; Clementi M; Valenti M; Fiorentini G; Cantore M; Kanavos E; Amicucci G
    In Vivo; 2006; 20(6A):715-8. PubMed ID: 17203752
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combined regimen of cisplatin, doxorubicin, and alpha-2b interferon in the treatment of advanced malignant pleural mesothelioma: a Phase II multicenter trial of the Italian Group on Rare Tumors (GITR) and the Italian Lung Cancer Task Force (FONICAP).
    Parra HS; Tixi L; Latteri F; Bretti S; Alloisio M; Gravina A; Lionetto R; Bruzzi P; Dani C; Rosso R; Cosso M; Balzarini L; Santoro A; Ardizzoni A
    Cancer; 2001 Aug; 92(3):650-6. PubMed ID: 11505411
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sarcomatoid malignant pleural mesothelioma treated with nivolumab: A case series.
    Hashimoto K; Ozasa H; Yoshizawa A; Yoshida H; Ogimoto T; Hosoya K; Yamazoe M; Ajimizu H; Funazo T; Yoshida H; Sakamori Y; Hirai T
    Oncol Lett; 2022 Nov; 24(5):402. PubMed ID: 36276492
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Brief report: a phase II study of sunitinib in malignant pleural mesothelioma. the NCIC Clinical Trials Group.
    Laurie SA; Gupta A; Chu Q; Lee CW; Morzycki W; Feld R; Foo AH; Seely J; Goffin JR; Laberge F; Murray N; Rao S; Nicholas G; Laskin J; Reiman T; Sauciuc D; Seymour L
    J Thorac Oncol; 2011 Nov; 6(11):1950-4. PubMed ID: 22005473
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A phase II study of intermittent sunitinib malate as second-line therapy in progressive malignant pleural mesothelioma.
    Nowak AK; Millward MJ; Creaney J; Francis RJ; Dick IM; Hasani A; van der Schaaf A; Segal A; Musk AW; Byrne MJ
    J Thorac Oncol; 2012 Sep; 7(9):1449-56. PubMed ID: 22895142
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immune-Checkpoint Inhibitors for Malignant Pleural Mesothelioma: A French, Multicenter, Retrospective Real-World Study.
    Assié JB; Crépin F; Grolleau E; Canellas A; Geier M; Grébert-Manuardi A; Akkache N; Renault A; Hauss PA; Sabatini M; Bonnefoy V; Cortot A; Wislez M; Gauvain C; Chouaïd C; Scherpereel A; Monnet I
    Cancers (Basel); 2022 Mar; 14(6):. PubMed ID: 35326648
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial.
    Kudo T; Hamamoto Y; Kato K; Ura T; Kojima T; Tsushima T; Hironaka S; Hara H; Satoh T; Iwasa S; Muro K; Yasui H; Minashi K; Yamaguchi K; Ohtsu A; Doki Y; Kitagawa Y
    Lancet Oncol; 2017 May; 18(5):631-639. PubMed ID: 28314688
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diffusion-weighted MRI of malignant pleural mesothelioma: preliminary assessment of apparent diffusion coefficient in histologic subtypes.
    Gill RR; Umeoka S; Mamata H; Tilleman TR; Stanwell P; Woodhams R; Padera RF; Sugarbaker DJ; Hatabu H
    AJR Am J Roentgenol; 2010 Aug; 195(2):W125-30. PubMed ID: 20651171
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial.
    Weber JS; Gibney G; Sullivan RJ; Sosman JA; Slingluff CL; Lawrence DP; Logan TF; Schuchter LM; Nair S; Fecher L; Buchbinder EI; Berghorn E; Ruisi M; Kong G; Jiang J; Horak C; Hodi FS
    Lancet Oncol; 2016 Jul; 17(7):943-955. PubMed ID: 27269740
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial.
    Sharma P; Retz M; Siefker-Radtke A; Baron A; Necchi A; Bedke J; Plimack ER; Vaena D; Grimm MO; Bracarda S; Arranz JÁ; Pal S; Ohyama C; Saci A; Qu X; Lambert A; Krishnan S; Azrilevich A; Galsky MD
    Lancet Oncol; 2017 Mar; 18(3):312-322. PubMed ID: 28131785
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Kang YK; Boku N; Satoh T; Ryu MH; Chao Y; Kato K; Chung HC; Chen JS; Muro K; Kang WK; Yeh KH; Yoshikawa T; Oh SC; Bai LY; Tamura T; Lee KW; Hamamoto Y; Kim JG; Chin K; Oh DY; Minashi K; Cho JY; Tsuda M; Chen LT
    Lancet; 2017 Dec; 390(10111):2461-2471. PubMed ID: 28993052
    [TBL] [Abstract][Full Text] [Related]  

  • 33. LUME-Meso: Design and Rationale of the Phase III Part of a Placebo-Controlled Study of Nintedanib and Pemetrexed/Cisplatin Followed by Maintenance Nintedanib in Patients With Unresectable Malignant Pleural Mesothelioma.
    Scagliotti GV; Gaafar R; Nowak AK; Reck M; Tsao AS; van Meerbeeck J; Vogelzang NJ; Nakano T; von Wangenheim U; Velema D; Morsli N; Popat S
    Clin Lung Cancer; 2017 Sep; 18(5):589-593. PubMed ID: 28690011
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase II study of vinflunine in malignant pleural mesothelioma.
    Talbot DC; Margery J; Dabouis G; Dark G; Taylor H; Boussemart H; Cadic V; Pinel MC; Rivière A; Ollivier L; Ruffié P
    J Clin Oncol; 2007 Oct; 25(30):4751-6. PubMed ID: 17947722
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Carboplatin plus pemetrexed as first-line treatment of patients with malignant pleural mesothelioma: a phase II study.
    Katirtzoglou N; Gkiozos I; Makrilia N; Tsaroucha E; Rapti A; Stratakos G; Fountzilas G; Syrigos KN
    Clin Lung Cancer; 2010 Jan; 11(1):30-5. PubMed ID: 20085865
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of nivolumab in Japanese patients with first recurrence of glioblastoma: an open-label, non-comparative study.
    Aoki T; Kagawa N; Sugiyama K; Wakabayashi T; Arakawa Y; Yamaguchi S; Tanaka S; Ishikawa E; Muragaki Y; Nagane M; Nakada M; Suehiro S; Hata N; Kuroda J; Narita Y; Sonoda Y; Iwadate Y; Natsumeda M; Nakazato Y; Minami H; Hirata Y; Hagihara S; Nishikawa R
    Int J Clin Oncol; 2021 Dec; 26(12):2205-2215. PubMed ID: 34586548
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nose in malignant mesothelioma-Prediction of response to immune checkpoint inhibitor treatment.
    Disselhorst MJ; de Vries R; Quispel-Janssen J; Wolf-Lansdorf M; Sterk PJ; Baas P
    Eur J Cancer; 2021 Jul; 152():60-67. PubMed ID: 34087572
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tsunami of immunotherapy reaches mesothelioma.
    Mielgo-Rubio X; Cardeña Gutiérrez A; Sotelo Peña V; Sánchez Becerra MV; González López AM; Rosero A; Trujillo-Reyes JC; Couñago F
    World J Clin Oncol; 2022 Apr; 13(4):267-275. PubMed ID: 35582652
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nivolumab-induced immune thrombocytopenia in a patient with malignant pleural mesothelioma.
    Sakakibara-Konishi J; Sato M; Sato MT; Kasahara K; Onozawa M; Mizugaki H; Kikuchi E; Asahina H; Shinagawa N; Konno S
    Respir Med Case Rep; 2020; 31():101170. PubMed ID: 32714828
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial.
    Larkin J; Minor D; D'Angelo S; Neyns B; Smylie M; Miller WH; Gutzmer R; Linette G; Chmielowski B; Lao CD; Lorigan P; Grossmann K; Hassel JC; Sznol M; Daud A; Sosman J; Khushalani N; Schadendorf D; Hoeller C; Walker D; Kong G; Horak C; Weber J
    J Clin Oncol; 2018 Feb; 36(4):383-390. PubMed ID: 28671856
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.